



CME Information

Thoracic

Surgeons

Course Description

The 19th Annual Perioperative & Critical Care Conference Online is designed to disseminate the latest techniques and management strategies in cardiovascular and thoracic (CVT) critical care and enhanced recovery after surgery (ERAS) for teams who provide care for patients undergoing CVT operations and interventional procedures. This 2.5 day event features dynamic and interactive presentations, hands-on demonstrations, scientific abstracts, and expert panel discussions designed for all members of the CVT critical care team.

Learning Objectives

Upon completion of this activity, participants should be able to

- Describe the elements of Enhanced Recovery After Surgery (ERAS), including: •
 - How to implement an enhanced recovery protocol,
 - Methodologies for reducing the use of blood products, avoiding acute kidney injury, and reducing 0 opioids for perioperative analgesia,
 - How to measure effectiveness of an ERAS program.
 - Evaluate strategies for optimizing the interaction and engagement of the interdisciplinary team during ICU rounds.
- Discuss the optimal management of postoperative atrial fibrillation. •
- Demonstrate techniques in ECMO management, use of ultrasound for cardiac and intravascular volume • status in postoperative patients, and management of postoperative cardiac emergencies.
- Describe elements of contemporary perioperative management of the heart failure patient.
- Explain the organization of the shock team.
- Describe the diagnosis and management of:
 - Heparin induced thrombocytopenia,
 - Neurological catastrophes after descending thoracic aortic surgery,
 - RV Failure. 0

Target Audience

This conference is designed for all members of the cardiothoracic and thoracic critical care team, including surgeons, cardiologists, interventionalists, intensivists, anesthesiologists, hospitalists, critical care nurses/nurse practitioners, perioperative registered nurses, physician assistants, catheter lab technicians, perfusionists, pharmacists, nutritionists, and respiratory therapists. In addition, surgical residents and cardiothoracic surgical fellows in training are encouraged to attend.

Accreditation Statement

The Society of Thoracic Surgeons is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Society of Thoracic Surgeons designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physician Assistants (PAs) may claim AMA PRA Category 1 Credits[™] for completing this activity.

The Society of Thoracic Surgeons Education Disclosure Policy

As a sponsor of continuing medical education accredited by the Accreditation Council for Continuing Medical Education (ACCME), The Society of Thoracic Surgeons requires that any individual who is in a position to control the content of an educational activity must disclose all financial relationships with any ineligible companies. This is to ensure that that all decisions related to the planning, faculty selection, delivery, and evaluation of accredited education are made without any influence or involvement from the owners and employees of an ineligible company. The ACCME defines ineligible companies as those whose "primary business is producing, marketing, selling, reselling, or distributing health care products used by or on patients." The question of whether a disclosed conflict situation could represent undue influence on the educational activity by an ineligible company or whether the disclosed information is sufficient to consider an abstract, presentation, or other educational enduring material to represent potentially biased information must be mitigated prior to an individual's involvement in STS educational programming.

Required disclosures must include all financial relationships with ineligible companies in the prior 24 months. Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual's institution receives the research grant and manages the funds.

Individuals who are owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in STS educational activities. There are three exceptions to this exclusion — employees of ineligible companies can participate as planners or faculty in these specific situations:

- 1. When the content of the activity is not related to the business lines or products of their employer/company.
- 2. When the content of the accredited activity is limited to basic science research, such as preclinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.
- 3. When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

Disclosure is mandatory for any person involved in the planning, management, presentation, and/or evaluation of STS educational activities. Failure to disclose all relationships with ineligible companies disqualifies the individual from being a planning committee member, a teacher, or an author of educational materials, and this individual cannot have any responsibility for the development, management, presentation, or evaluation of STS educational activities. This requirement is intended neither to imply any impropriety of such relationships nor to prejudice any individual planner, presenter or author. It is merely to identify such relationships through full disclosure, and to allow STS to assess and mitigate potential influences on the educational activity prior to the planning and implementation of an educational activity. Speakers are required to disclose that they have nothing to disclose if this is the case.

Additionally, the fact that the presentation, paper, or other educational product describes (a) the use of a device, product, or drug that is not FDA approved or (b) an off-label use of an approved device, product, or drug or (c) a new or evolving topic advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning must also be disclosed. This requirement has been adopted in response to FDA policy and case law involving medical societies, and is not intended to prohibit or inhibit independent presentation or discussion regarding the uses of devices, products, and drugs as described in (a) or (b) above.

All relevant financial information will be disclosed to learners before they engage with or access STS educational content and activities. For live presentations, all disclosures must be stated orally and on a slide at the beginning of the presentation and will be noted in published material related to the activity. Disclosure to learners will include each of the following:

- 1. The names of the individuals with relevant financial relationships.
- 2. The names of the ineligible companies with which they have relationships.

- 3. The nature of the relationships.
- 4. A statement that all relevant financial relationships have been mitigated.

Disclosure to learners must not include ineligible companies' corporate or product logos, trade names, or product group messages. If applicable, the absence of relevant financial relationships with ineligible companies will also be disclosed to learners.

In order to ensure that STS educational activities are free of marketing or sales of products and services, faculty must not actively promote or sell products or services that serve their professional or financial interests during accredited education. Slides, handouts, and other materials utilized as part of an educational activity cannot contain any advertising, trade names or a product group message.

Amended by the STS Executive Committee: June 9, 2021

Planning Task Force, Faculty, and STS Staff Disclosure Information

Unless otherwise noted, the individuals below have had no commercial relationships with ineligible companies in the past 24 months. All commercial relationships have been mitigated.

Planning Task Force

Rakesh C. Arora, MD, PhD Cleveland Clinic, Cleveland OH Commercial Relationships: AVIR Pharma, Inc. – Speakers Bureau/Honoraria; Edwards Lifesciences – Speakers Bureau/Honoraria

Subhasis Chatterjee, MD Baylor College of Medicine/Texas Heart Institute, Houston, TX Commercial Relationships: Baxter Pharmaceutical – Consultant/Advisory Board; Eagle Pharmaceutical – Consultant/Advisory Board; Edwards Lifesciences – Consultant/Advisory Board; La Jolla Pharmaceutical – Consultant/Advisory Board

James (Jake) H. Abernathy III, MD, MPH Johns Hopkins, Baltimore, MD Commercial Relationships: Becton Dickinson – Consultant/Advisory Board

Clauden Louis, MD, MPH, MS Baylor St. Luke's Medical Center/Texas Heart Institute, Houston, TX

HelenMari Merritt-Genore, DO Nebraska Methodist Hospital Commercial Relationships: AtriCure – Consultant/Advisory Board

Vicki Morton-Bailey, DNP, AGNP-BC Providence Anesthesiology Associates, Charlotte, NC

Sarah Schettle, PA-C, MS, MBA Mayo Clinic, Rochester, MN Commercial Relationships: Abbott – Consultant; Medtronic – Consultant, Speakers Bureau/Honoraria

Faculty

Frank A. Baciewicz, Jr., MD Detroit Medical Center, Detroit, MI

Anna L. Ciullo, MD University of Utah Health, Salt Lake City, UT Cheryl Crisafi, MSN Baystate Health, Springfield, MA Commercial Relationships: Abbott Nutrition – Speakers Bureau

Jean Deschamps, MDCM Cleveland Clinic, Cleveland, OH

Maren Downing, Meng WakeMed Health and Hospitals, Raleigh, NC

Daniel T. Engelman, MD Baystate Health, Springfield, MA

Commercial Relationships: Alexion – Consultant; AM Pharma – Drug Trial Steering Committee; Astellas Pharmaceuticals – Drug Trial Steering Committee; Edwards Lifesciences – Device Safety Monitoring Board; Medela – Advisory Board; Renibus – Drug Trial Steering Committee; Rockwell Medical – Advisory Board; Terumo Medical Corporation – Advisory Board

Michael C. Grant, MD, MSE Johns Hopkins, Baltimore, MD

Jonathan Haft, MD University of Michigan Health

Morgan L. King, HBSc. Queen's University, Kingston, ON

Yoan Lamarche, MD Institut de Cardiologie de Montréal and Hôpital du Sacré-Coeur de Montréal, Montreal, QC

Thomas E. MacGillivray, MD Houston Methodist, Houston, TX

Nicholas Mighion, RN HCA Florida North Florida Hospital, Gainesville, FL

Nathalie Roy, MD Boston Children's Hospital, Boston, MA

Raghad H. Said, MD Hackensack University Medical Center, Hackensack, NJ

Lee Ann Santore, MSIV Renaissance School of Medicine at Stony Brook University, Stony Brook, NY

Andrew Shaw, MD Cleveland Clinic, Cleveland, OH **Commercial Relationships:** AM Pharma – Advisory Board; Astellas Pharmaceuticals – Advisory Board; Edwards Lifesciences – Advisory Board; Fresenius – Advisory Board

Gurmeet Singh, MD, MSc University of Alberta, Edmonton, AB Edward G. Soltesz, MD Cleveland Clinic, Cleveland, OH Commercial Relationships: Abbott – Speakers Bureau/Honoraria; Abiomed – Speakers Bureau/Honoraria; AtriCure – Speakers Bureau/Honoraria

Ronald Stewart, MD University of Texas Health, San Antonio, TX

Nicholas R. Teman, MD University of Virginia Health, Heart and Vascular Center, Charlottesville, VA

Glenn J. R. Whitman, MD Johns Hopkins, Baltimore, MD Commercial Relationships: Avania/Cellphire – Advisory Board; GWBN, LLC – Owner

STS Staff

Scott Bradbury, MS Vice President of Education

Amy Cacich, CMP Senior Manager, Meetings and Conventions

Meredith Herzog Associate Director of Education

Wesley Peart, MA Education Manager

Melisa Puthenmadom, MS Senior E-Learning Coordinator

Gabriele Trainyte Marketing & Communications Coordinator